179 related articles for article (PubMed ID: 34953482)
1. Biological therapy in Psoriasis: An emphasis on its dermatologic adverse events.
Palakornkitti P; Nimmannitya K; Rattanakaemakorn P
Asian Pac J Allergy Immunol; 2021 Dec; 39(4):215-230. PubMed ID: 34953482
[TBL] [Abstract][Full Text] [Related]
2. Risk of Paradoxical Eczema in Patients Receiving Biologics for Psoriasis.
Al-Janabi A; Alabas OA; Yiu ZZN; Foulkes AC; Eyre S; Khan AR; Reynolds NJ; Smith CH; Griffiths CEM; Warren RB;
JAMA Dermatol; 2024 Jan; 160(1):71-79. PubMed ID: 38055239
[TBL] [Abstract][Full Text] [Related]
3. Adverse events resulting in withdrawal of biologic therapy for psoriasis in real-world clinical practice: A Canadian multicenter retrospective study.
Kim WB; Marinas JE; Qiang J; Shahbaz A; Greaves S; Yeung J
J Am Acad Dermatol; 2015 Aug; 73(2):237-41. PubMed ID: 26026334
[TBL] [Abstract][Full Text] [Related]
4. Biologics and Small Molecule Agents in Allergic and Immunologic Skin Diseases.
Kaufman BP; Alexis AF
Curr Allergy Asthma Rep; 2018 Aug; 18(10):55. PubMed ID: 30171358
[TBL] [Abstract][Full Text] [Related]
5. Biologic Treatment in Elderly Patients With Psoriasis: A Systematic Review.
Sandhu VK; Ighani A; Fleming P; Lynde CW
J Cutan Med Surg; 2020; 24(2):174-186. PubMed ID: 31950853
[TBL] [Abstract][Full Text] [Related]
6. Vaccination Recommendations for Psoriasis and Atopic Dermatitis Patients on Biologic Therapy: A Practical Guide.
Fan R; Cohen JM
Yale J Biol Med; 2022 Jun; 95(2):249-255. PubMed ID: 35782480
[TBL] [Abstract][Full Text] [Related]
7. Biologics for chronic inflammatory skin diseases: an update for the clinician.
Yao Y; Ravn Jørgensen AH; Thomsen SF
J Dermatolog Treat; 2020 Mar; 31(2):108-130. PubMed ID: 30827126
[TBL] [Abstract][Full Text] [Related]
8. Safety of Systemic Agents for the Treatment of Pediatric Psoriasis.
Bronckers IMGJ; Seyger MMB; West DP; Lara-Corrales I; Tollefson M; Tom WL; Hogeling M; Belazarian L; Zachariae C; Mahé E; Siegfried E; Philipp S; Szalai Z; Vleugels RA; Holland K; Murphy R; Baselga E; Cordoro K; Lambert J; Alexopoulos A; Mrowietz U; Kievit W; Paller AS;
JAMA Dermatol; 2017 Nov; 153(11):1147-1157. PubMed ID: 28903160
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of Risk of Major Adverse Cardiovascular Events With Biologic Therapy in Patients With Psoriasis.
Bissonnette R; Kerdel F; Naldi L; Papp K; Galindo C; Langholff W; Tang KL; Szapary P; Fakharzadeh S; Srivastava B; Goyal K; Gottlieb AB
J Drugs Dermatol; 2017 Oct; 16(10):1002-1013. PubMed ID: 29036254
[TBL] [Abstract][Full Text] [Related]
10. Malignancy rates in a large cohort of patients with systemically treated psoriasis in a managed care population.
Asgari MM; Ray GT; Geier JL; Quesenberry CP
J Am Acad Dermatol; 2017 Apr; 76(4):632-638. PubMed ID: 28162854
[TBL] [Abstract][Full Text] [Related]
11. Adverse events associated with discontinuation of the biologics/classic systemic treatments for moderate-to-severe plaque psoriasis: data from the Spanish Biologics Registry, Biobadaderm.
Belinchón I; Ramos JM; Carretero G; Ferrándiz C; Rivera R; Daudén E; De la Cueva-Dobao P; Gómez-García FJ; Herrera-Ceballos E; Sánchez-Carazo JL; López-Estebaranz JL; Alsina M; Ferrán M; Torrado R; Carrascosa JM; Llamas-Velasco M; Ortiz PL; García-Doval I; Descalzo MA;
J Eur Acad Dermatol Venereol; 2017 Oct; 31(10):1700-1708. PubMed ID: 28485816
[TBL] [Abstract][Full Text] [Related]
12. Treatment modalities and risk of adverse events associated with biologic therapy: A 10-year observational review of the Australasian Psoriasis Registry.
Doolan BJ; Koye D; Ling J; Cains GD; Baker C; Foley P; Dolianitis C
Australas J Dermatol; 2021 Feb; 62(1):e47-e54. PubMed ID: 32885846
[TBL] [Abstract][Full Text] [Related]
13. New and emerging biologic therapies for moderate-to-severe plaque psoriasis: mechanistic rationales and recent clinical data for IL-17 and IL-23 inhibitors.
Gaspari AA; Tyring S
Dermatol Ther; 2015; 28(4):179-93. PubMed ID: 26201310
[TBL] [Abstract][Full Text] [Related]
14. Cancer risks in patients with psoriasis administered biologics therapy: a nationwide population-based study.
Jung JM; Kim YJ; Chang SE; Lee MW; Won CH; Lee WJ
J Cancer Res Clin Oncol; 2023 Dec; 149(19):17093-17102. PubMed ID: 37755577
[TBL] [Abstract][Full Text] [Related]
15. Predictive factors for adverse dermatological events during pegylated/interferon alpha and ribavirin treatment for hepatitis C.
Li Z; Zhang Y; An J; Feng Y; Deng H; Xiao S; Ji F
J Clin Virol; 2014 Jul; 60(3):190-5. PubMed ID: 24830933
[TBL] [Abstract][Full Text] [Related]
16. Safety and tolerability of tumor necrosis factor-α inhibitors in psoriasis: a narrative review.
Semble AL; Davis SA; Feldman SR
Am J Clin Dermatol; 2014 Feb; 15(1):37-43. PubMed ID: 24281790
[TBL] [Abstract][Full Text] [Related]
17. Management of cutaneous side effects of inflammatory bowel disease therapy: A dermatologic viewpoint.
Lee J; Lemons N; Lorenze A; Chowdhary TS; Zinn Z; Gayam S
J Gastroenterol Hepatol; 2021 Dec; 36(12):3278-3285. PubMed ID: 34139789
[TBL] [Abstract][Full Text] [Related]
18. Paradoxical Psoriasis.
Abdelghaffar M; Kottilil S; Murphy MJ; Cohen JM; Damsky W
Dermatol Clin; 2024 Jul; 42(3):471-480. PubMed ID: 38796276
[TBL] [Abstract][Full Text] [Related]
19. A multinational, prospective, observational study to estimate complete skin clearance in patients with moderate-to-severe plaque PSOriasis treated with BIOlogics in a REAL world setting (PSO-BIO-REAL).
Seneschal J; Lacour JP; Bewley A; Faurby M; Paul C; Pellacani G; De Simone C; Horne L; Sohrt A; Augustin M; Hammond E; Reich K
J Eur Acad Dermatol Venereol; 2020 Nov; 34(11):2566-2573. PubMed ID: 32364296
[TBL] [Abstract][Full Text] [Related]
20. Safety of Biologic Therapy in Older Patients With Immune-Mediated Diseases: A Systematic Review and Meta-analysis.
Borren NZ; Ananthakrishnan AN
Clin Gastroenterol Hepatol; 2019 Aug; 17(9):1736-1743.e4. PubMed ID: 30616024
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
